Our take on the latest news and views on data.

Relevant company news, articles, podcasts, and blog posts.

Recent Posts

Industry Trends

Clinical Trial Trends

Disease Area Trends

Recent Tweets

Abbisko finished enrolling all patients for the global phase III TGCT trial of their CSF-1R inhibitor Pimicotinib.

More Info: https://pryzm.ozmosi.com/product/22476 $XBI $IBB $XPH $PPH

🚀🚨 Biotech Catalyst Watchlist Events Coming Tomorrow!!! 📆 #AACR24 @AACR
👇👇👇

April 9th, 2024
$IOBT IO102-IO103 - Oncology Solid Tumor Unspecified (P0)
$CGEN COM-503 - Oncology Solid Tumor Unspecified (P0)
$BGNE LBL-007 - Oncology Solid Tumor Unspecified (P0)
$IPHA IPH-45…

Preclinical data on GV20-0251 for solid tumors targeting IGSF8 presented by GV20 Therapeutics at AACR Annual Meeting 2024.

More Info: https://pryzm.ozmosi.com/product/28023 $XBI $IBB $XPH $PPH

$BPTS, PARIS:ALBPS Biophytis initiates phase 2 clinical trial for obesity using BIO101 (20-hydroxyecdysone).

More Info: https://pryzm.ozmosi.com/product/19822 $XBI $IBB $XPH $PPH

Load More

Get Started with OZMOSI

We synthesize and process insights, delivering what you need quickly, effectively, and efficiently.

600 Warren Ave,
Spring Lake, NJ 07762